We are live on ! Find out more
SLRN

ACELYRIN

Delisted

SLRN was delisted on the 21st of May, 2025.

125 hedge funds and large institutions have $276M invested in ACELYRIN in 2024 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 40 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more call options, than puts

Call options by funds: $22K | Put options by funds: $4K

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

10% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 40

2% more funds holding

Funds holding: 122125 (+3)

0.28% more ownership

Funds ownership: 87.41%87.69% (+0.28%)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

36% less capital invested

Capital invested by funds: $430M → $276M (-$154M)

Holders
125
Holders Change
+3
Holders Change %
+2.46%
% of All Funds
1.64%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
18
Increased
44
Reduced
40
Closed
14
Calls
$22K
Puts
$4K
Net Calls
+$18K
Net Calls Change
+$136K

SLRN Hedge Fund Activity: Q4 2024 in Review

125 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q4 2024, worth a combined $276M — down 36% from $430M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new SLRN positions and 14 closed out — a net gain of 4 holders — while 44 added to existing stakes and 40 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $11.8M. The largest seller was Citadel Advisors, cutting an estimated $11.2M.

  • 125 institutional investors held ACELYRIN (SLRN) as of Q4 2024, up from 122 in Q3 2024.
  • Funds reported $276M of ACELYRIN stock for Q4 2024, down 36% quarter-over-quarter.
  • 18 funds opened new ACELYRIN positions in Q4 2024 and 14 closed out, a net change of +4 holders.
  • The largest ACELYRIN buyer in Q4 2024 was T. Rowe Price Investment Management, an estimated $11.8M added.
  • The largest ACELYRIN seller in Q4 2024 was Citadel Advisors, an estimated $11.2M sold.

Based on aggregated 13F filings for Q4 2024.